ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $26.00 Price Target at Royal Bank of Canada

ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price target reduced by Royal Bank of Canada from $29.00 to $26.00 in a research report report published on Wednesday, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ACAD has been the subject of several other research reports. Cantor Fitzgerald reissued an […]

Leave a Reply

Your email address will not be published.

Previous post FY2024 Earnings Forecast for ASP Isotopes Inc. (NASDAQ:ASPI) Issued By HC Wainwright
Next post Analysts Issue Forecasts for Airbnb, Inc.’s Q3 2024 Earnings (NASDAQ:ABNB)